Neurogene (NASDAQ:NGNE) is a biotechnology company developing gene therapy treatments for nervous system disorders. They utilize adeno-associated virus (AAV) vectors to deliver corrective genetic material to target cells, potentially offering a new approach to treating neurological conditions. Neurogene's pipeline might focus on treatments for rare or debilitating diseases with limited therapeutic options. While they are still in the pre-commercial stages, with clinical trials ongoing, Neurogene's gene therapy research holds promise for offering life-changing treatments for patients with neurological conditions.